{
    "clinical_study": {
        "@rank": "58880", 
        "arm_group": [
            {
                "arm_group_label": "Biological treatment", 
                "arm_group_type": "Experimental", 
                "description": "Patients with high disease activity receiving biological treatment according to rheumatologic indication:\netanercept 50 mg s.c. every week\nadalimumab 40 mg s.c. every 2 weeks\ncertolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks\ninfliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks"
            }, 
            {
                "arm_group_label": "control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients with high disease activity receiving other than biological treatment and receiving placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the influence of anti  tumor necrosis factor-alpha\n      (TNF-\u03b1) treatment on blood pressure, endothelial function and immune cell phenotype in\n      patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis."
        }, 
        "brief_title": "Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis", 
        "condition": [
            "Rheumatoid Arthritis", 
            "Psoriatic Arthritis", 
            "Ankylosing Spondylitis", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic", 
                "Arthritis, Rheumatoid", 
                "Hypertension", 
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For patients suffering from rheumatoid arthritis:\n\n          -  rheumatoid arthritis diagnosed based on The American Rheumatism Association Criteria\n             from 1987\n\n          -  ineffective treatment with 2 disease-modifying antirheumatic drugs (DMARDs) for 6\n             months each, including treatment with maximal doses of methotrexate for at least 3\n             months (or intolerance to treatment)\n\n          -  high disease activity - Disease Activity Score 28 (DAS 28)  > 5,1 measured twice,\n             with a 1-month interval\n\n          -  for patients with mainly lower limbs affected with DAS 28  > 3,7\n\n        For patients suffering from Ankylosing Spondylitis:\n\n          -  Ankylosing Spondylitis diagnosed based on Modified New York Criteria\n\n          -  ineffective treatment with 2 non-steroidal anti-inflammatory drugs (administered\n             separately) in maximal recommended or maximal tolerated dose for 3 months\n\n          -  high disease activity -Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >\n             4 measured twice, with a 12-week interval\n\n          -  spinal pain > 4cm on 10cm Visual Analogue Scale (VAS) measured twice, with a 12-week\n             interval\n\n          -  general disease activity assessment > 5 (0-10 scale) performed after the 2nd VAS and\n             BASDAI assessment\n\n        For patients suffering from Psoriatic Arthritis:\n\n        - Psoriatic arthritis diagnosed based on the Bennett or Classification Criteria for\n        Psoriatic Arthritis (CASPAR Criteria)\n\n        If peripheral joints are affected:\n\n        active disease assessed twice, with a 4-week interval on stable treatment, after 2 DMARDs\n        treatment for at least 4 months\n\n        Criteria of active disease (all have to be met):\n\n          -  At least 5 out of 66 joints swollen - assessed twice, with a 4-week interval\n\n          -  At least 5 out of 68 joints tender - assessed twice, with a 4-week interval\n\n          -  general disease activity assessment of 4 or 5 in the Likert scale (0- 5 scale)\n             performed by patient\n\n          -  general disease activity assessment of 4 or 5 in the Likert scale (0- 5 scale)\n             performed by physician\n\n          -  general disease activity assessment > 5 (0-10 scale) performed after 2nd assessment\n             of number of tender and swollen joints\n\n        If axial joints are affected:\n\n          -  Sacroiliac joints affected according to the New York Criteria of Ankylosing\n             Spondylitis\n\n          -  Active and severe disease assessed twice, with a 12-week interval, stable treatment,\n             ineffective treatment with 2 nonsteroidal anti-inflammatory drugs (administered\n             separately) in maximal recommended or maximal tolerated dose for 3 months each\n\n        Criteria of active disease (all must be present):\n\n          -  BASDAI > 4 measured twice, with a 12-week interval\n\n          -  spinal pain > 4cm on 10 cm in the VAS measured twice, with a 12-week interval\n\n          -  general disease activity assessment > 5 (0-10 scale) Patients can take steroid in\n             stable dose within one month - maximal dose 10mg/day of prednisone.\n\n        Exclusion Criteria:\n\n          -  non-consenting patient\n\n          -  pregnancy\n\n          -  breast-feeding\n\n          -  allergy for the drug or any component\n\n          -  cardiac insufficiency (NYHA III or IV)\n\n          -  active infection\n\n          -  infection within the last 3 months: hepatitis, pneumonia, pyelonephritis\n\n          -  opportunistic infection within the last 2 months: active infection of\n             cytomegalovirus, Pneumocystis carinii\n\n          -  joint infection within the last 12 months\n\n          -  endoprosthesis infection within the last 12 months or any time if the joint was not\n             replaced\n\n          -  exacerbation of lung-, kidney-, liver-  or heart insufficiency during treatment\n\n          -  demyelinating disease or its symptoms\n\n          -  pancytopenia or aplastic anemia\n\n          -  pre-cancer stage\n\n          -  neoplasm within the last 5 years including solid tumors and neoplasm of\n             haematopoietic or lymphatic system with risk of recurrence  or progression\n\n          -  active alcoholic disease\n\n          -  chronic liver disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132234", 
            "org_study_id": "UJ-KChWiMWsi-Reu"
        }, 
        "intervention": [
            {
                "arm_group_label": "Biological treatment", 
                "description": "biological treatment according to rheumatologic indication", 
                "intervention_name": "Etanercept", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Biological treatment", 
                "description": "biological treatment according to rheumatologic indication", 
                "intervention_name": "Adalimumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Biological treatment", 
                "description": "biological treatment according to rheumatologic indication", 
                "intervention_name": "Certolizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Biological treatment", 
                "description": "biological treatment according to rheumatologic indication", 
                "intervention_name": "Infliximab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "TNFR-Fc fusion protein", 
                "Infliximab", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "last_name": "Bogdan Batko, MD, PhD", 
                "phone": "48126876261"
            }, 
            "contact_backup": {
                "last_name": "Agata Schramm, MD", 
                "phone": "48126876210"
            }, 
            "facility": {
                "address": {
                    "city": "Krakow, Skarbowa 4", 
                    "country": "Poland", 
                    "zip": "31-121"
                }, 
                "name": "Katedra Chor\u00f3b Wewn\u0119trznych i Medycyny Wsi, Uniwersytet Jagiello\u0144ski"
            }, 
            "investigator": [
                {
                    "last_name": "Tomasz Guzik, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Bogdan Batko, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Agata Schramm, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis", 
        "other_outcome": {
            "description": "determination of subsets, activation markers, intracellular cytokine production", 
            "measure": "Changes  in immune cell subset populations from baseline", 
            "safety_issue": "Yes", 
            "time_frame": "prior to receiving anti-TNF-\u03b1 treatment, 12 weeks"
        }, 
        "overall_official": [
            {
                "affiliation": "Jagiellonian University", 
                "last_name": "Tomasz Guzik, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Department of Rheumatology, J. Dietl Hospital, Krakow, Poland", 
                "last_name": "Bogdan Batko, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Ambulatory Blood Pressure Monitoring (ABPM)", 
            "measure": "Change from baseline in blood pressure", 
            "safety_issue": "Yes", 
            "time_frame": "prior to receiving anti-TNF-\u03b1  treatment, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132234"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jagiellonian University", 
            "investigator_full_name": "Tomasz Guzik", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Flow Mediated Dilatation / Endo Pat", 
            "measure": "Change from baseline in endothelial function", 
            "safety_issue": "Yes", 
            "time_frame": "prior to receiving anti-TNF-\u03b1 treatment, 12 weeks"
        }, 
        "source": "Jagiellonian University", 
        "sponsors": {
            "collaborator": {
                "agency": "Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jagiellonian University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}